Chemoprevention of Prostate Cancer via Estrogen Receptor B Agonists

通过雌激素受体 B 激动剂化学预防前列腺癌

• 批准号: 8739519
• 负责人: Michael Pawlita
• 金额: $ 68.63万
• 依托单位: IIT RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-18 至 2015-09-17
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8739519
• 关键词: Agonist; Androgens; Apoptosis; Cell Proliferation; Chemoprevention; Chemopreventive Agent; Estrogen Receptors; Gene Expression; Malignant neoplasm of prostate; Mediating; Mus; Nitrosourea Compounds; Prostate; Protocols documentation; Rattus; Signal Pathway; Testosterone; prostate carcinogenesis; tumor initiation; tumor progression

The overall objective of this task order is to evaluate two selective estrogen receptor  (ER) agonists, Prinaberel (ERB-041) and LY500307, in inhibition of androgen-dependent prostate carcinogenesis induced in the Wistar-Unilever rat by N-methy-N-nitrosourea (MNU) plus testosterone. Furthermore, this task order also requires studying the chemopreventive efficacy of these two agents in association with specific signaling pathway(s) involved in cell proliferation, differentiation, and apoptosis in prostate.

该任务顺序的总体目标是评估两种选择性雌激素受体  (ER) 激动剂 Prinaberel (ERB-041) 和 LY500307 对 N-甲基-联合利华 Wistar-Unilever 大鼠诱导的雄激素依赖性前列腺癌的抑制作用N-亚硝基脲 (MNU) 加睾酮。此外，该任务顺序还需要研究这两种药物的化学预防功效与涉及前列腺细胞增殖、分化和凋亡的特定信号通路的关系。